Compare GE Vernova Inc (GEV) vs Hims and Hers Health Inc (HIMS) Price & Performance

GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net margin, though valuation metrics appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent news highlights the company securing the first US construction permit for its BWRX-300 small modular reactor and benefiting from AI-driven power demand growth.

GEV presents growth potential from its $176 billion backlog and AI infrastructure demand, but faces valuation concerns and execution risks in its wind power segment. Analyst consensus remains strongly bullish with 75.86% buy ratings and $1,270 price target, representing 27% upside from current levels. Key risks include competitive pressures and the challenge of maintaining current premium valuation multiples.

HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.

The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.